Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label randomized study of oral BI 685509 alone or with empagliflozin in clinically significant portal hypertension in compensated cirrhosis
MOH_2022-11-21_012175Phase 2Not yet recruiting
- Sponsor
- : Boehringer Ingelheim RCV GmbH & Co KG
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of avenciguat and empagliflozin in Cirrhosis and Portal Hypertension (PH) (4 arms), sponsored by : Boehringer Ingelheim RCV GmbH & Co KG. Primary endpoint: Percent change from baseline in hepatic venous pressure gradient after 8 weeks. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
avenciguatempagliflozin
03
Conditions
CirrhosisPortal Hypertension (PH)
Beyond the preview
Go deeper on MOH_2022-11-21_012175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-11-21_012175.